Changes in MIC Within a Global Collection of Acinetobacter baumannii Collected as Part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages 101-112

  Morfin Otero, Rayo ^a   Dowzicky, Michael J ^b  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b PFIZER INC   (United States)

Author keywords

Acinetobacter; Antimicrobial resistance; MIC creep; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CRITERION RELATED VALIDITY; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AFRICA; ANTI-BACTERIAL AGENTS; ASIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; HUMANS; INTENSIVE CARE UNITS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST; MINOCYCLINE; NORTH AMERICA; TIME FACTORS;

EID: 84856179480     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.11.028     Document Type: Article

References (26)

1. Zavascki A.P., Carvalhaes C.G., Picão R.C., et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010, 8:71-93.
2. Falagas M.E., Karveli E.A., Siempos I.I., Vardakas K.Z. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 2008, 136:1009-1019.
3. Livermore D.M. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64(Suppl 1):i29-i36.
4. Briceño D.F., Quinn J.P., Villegas M.V. Treatment option for multidrug-resistant nonfermentors. Expert Rev Anti Infect Ther 2010, 8:303-315.
5. Giamarellou H., Poulakou G. Multidrug-resistant gram-negative infections: what are the treatment options?. Drugs 2009, 69:1879-1901.
6. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard 2003, National Committee for Clinical Laboratory Standards (NCCLS), Document M7-A6. NCCLS document M7-A6 (ISBN 1-56238-486-4), National Committee for Clinical Laboratory Standards [now Clinical and Laboratory Standards Institute], Wayne, Pa. 6th ed.
7. Performance Standard for Antimicrobial Susceptibility Testing 2010, Clinical and Laboratory Standards Institute (CLSI), Document M100-S20, Clinical and Laboratory Standards Institute, Wayne, Pa.
8. Pillar C.M., Draghi D.C., Dowzicky M.J., Sahm D.F. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 2008, 46:2862-2867.
9. Sokal R.R., Rohlf F.J. Biometry: Principles and Practice of Statistics in Biological Research 1995, WH Freeman & Co Ltd, New York, NY. 3rd ed.
10. Sader H.S., Fey P.D., Fish D.N., et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009, 53:4127-4132.
11. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
12. Alós J.I., García-Cañas A., García-Hierro P., et al. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008, 62:773-775.
13. MacGowan A.P. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008, 62(Suppl 2):ii105-ii114.
14. Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007, 45:3352-3359.
15. Mera R.M., Miller L.A., Amrine-Madsen H., et al. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010, 16:209-215.
16. Wadl M., Heckenbach K., Noll I., et al. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German university hospitals, 2002-2006. Infection 2010, 38:47-51.
17. Mendes R.E., Farrell D.J., Sader H.S., et al. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn Microbiol Infect Dis 2010, 68:307-311.
18. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63:775-780.
19. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62:45-55.
20. Kollef M.H., Micek S.T., Dellinger R.P. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005, 33:1845-1853.
21. Ye J.J., Huang C.T., Shie S.S., et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010, 5:e9947.
22. Dizbay M., Tunccan O.G., Sezer B.E., et al. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis 2010, 42:741-746.
23. Klein J.O. Maxwell Finland: a remembrance. Clin Infect Dis 2002, 34:725-729.
24. Jones R.N. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. J Antimicrob Chemother 2000, 46(Suppl B):1-8.
25. Reddy T., Chopra T., Marchaim D., et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 2010, 54:2235-2238.
26. Turton J.F., Kaufmann M.E., Warner M., et al. A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect 2004, 58:170-179.